Brief: Omega Therapeutics Announces Promising Preliminary Clinical Data For Otx-2002 From Ongoing Mychelangelo I Trial

Omega Liquidating

26/09/2023 12:24

Sept 26 (Reuters) - Omega Therapeutics Inc  OMGA.O :
    * OMEGA THERAPEUTICS ANNOUNCES PROMISING PRELIMINARY
CLINICAL DATA
FOR OTX-2002 FROM ONGOING MYCHELANGELO™ I TRIAL
    * OMEGA THERAPEUTICS INC - CLINICAL PROOF-OF-PLATFORM
ESTABLISHED;
POTENTIAL APPLICABILITY ACROSS A BROAD RANGE OF DISEASES
    * OMEGA THERAPEUTICS INC - AT BOTH DOSE LEVELS, OTX-2002 WAS
GENERALLY WELL TOLERATED, WITH NO DOSE-LIMITING TOXICITIES.
    * OMEGA THERAPEUTICS INC - EXPECTS TO INITIATE EXPANSION
COHORTS
IN MONOTHERAPY AND IN COMBINATION WITH STANDARD OF CARE
THERAPIES.
    * OMEGA THERAPEUTICS INC - AT BOTH DOSE LEVELS, OTX-2002 WAS
GENERALLY WELL TOLERATED, WITH NO DOSE-LIMITING TOXICITIES
    * OMEGA THERAPEUTICS INC - MAJORITY OF ADVERSE EVENTS
OBSERVED IN
TRIAL WERE GRADE 1 OR 2
    * OMEGA THERAPEUTICS INC - OTX-2002 CONTINUES TO ADVANCE IN
MONOTHERAPY DOSE ESCALATION

Source text for Eikon:  ID:nGNX4fydH6 
Further company coverage:  OMGA.O 

 ((Reuters.Briefs@thomsonreuters.com;))